Lord Aberdare
Main Page: Lord Aberdare (Crossbench - Excepted Hereditary)(1 year, 9 months ago)
Lords ChamberTo ask His Majesty’s Government what steps they are taking to increase the access to minimally invasive cancer therapies.
My Lords, I beg leave to ask the Question standing in my name on the Order Paper, and I declare my registered interest as a trustee of the UK Focused Ultrasound Foundation.
NHS England’s specialised commissioning team has been undertaking work to expand the number of providers offering minimally invasive cancer therapies such as selective internal radiation therapy. The market engagement and prior information notice aspects of this have now been completed, with regional teams now putting in place the necessary contractual arrangements with NHS trusts.
My Lords, I thank the Minister for that Answer and welcome him to the Dispatch Box. Minimally invasive cancer therapies such as focused ultrasound, SIRT, which he mentioned, cryoablation and radioligand therapy, offer significant benefits both to patients to the NHS: faster recovery times; reduced pain; fewer side effects; and less pressure on NHS facilities and staff. How will the 10-year cancer plan reflect the need to increase awareness of these therapies among patients and clinicians and increase access to them? Will the Government’s proposed workforce plan ensure the availability of enough interventional radiologists to deliver MICTs at the scale needed?
My Lords, I pay tribute to the noble Lord and the work that he has done on the All-Party Parliamentary Group on Minimally Invasive Cancer Therapies. In 2022-23, Health Education England is continuing to take forward priorities identified in the cancer workforce plan phase 1 and is investing an additional £50 million in 2022-23 to further expand the cancer and diagnosis workforce. Spending plans for individual budgets in 2023-24 to 2024-25 inclusive are subject to a detailed financial planning exercise and will be finalised in due course.